https://www.kluspharma.com/news/kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-to-develop-and-commercialize-novel-oncology-therapeutics 2025-12-05 https://www.kluspharma.com/news/klus-pharma-to-attend-2025-world-adc-san-diego-summit 2025-09-25 https://www.kluspharma.com/news/kelun-biotech-to-present-clinical-updates-for-key-adc-programs-at-2025-esmo 2025-09-25 https://www.kluspharma.com/news/kelun-biotech-to-present-results-of-six-clinical-studies-at-2025-asco-annual-meeting 2025-12-05 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-novel-adc-drug-skb518-receives-ind-clearance-from-u.s.-food-and-drug-administration-(fda) 2025-09-25 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-radionuclide-drug-conjugate--(rdc)-skb107-receives-ind-approval-from-nmpa 2025-09-25 https://www.kluspharma.com/news/kelun-biotech's-trop2-adc-sacituzumab-tirumotecan-(sac-tmt)-approved-for-marketing-in-egfrm-nsclc-by-nmpa 2025-04-24 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-sacituzumab-tirumotecan-(sac-tmt)-study-results-presented-at-2025-asco-genitourinary-cancers-symposium 2025-04-22 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-product-cetuximab-n01-injection-approved-for-marketing-by-nmpa-of-china 2025-03-31 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-novel-adc-skb445-receives-ind-approval-from-nmpa-in-china 2025-02-13 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-product-tagitanlimab-approved-for-marketing-in-second-indication-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-patients-with-recurrent-or-metastatic-npc 2025-03-10 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-her2-adc-trastuzumab-botidotin-(a166)-second-nda-accepted-by-nmpa 2025-02-07 https://www.kluspharma.com/news/kelun-biotech's-anti-pd-l1-(tagitanlimb)-receives-nmpa-approval-for-marketing 2025-01-23 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-trop2-adc-sacituzumab-tirumotecan-(sac-tmt%2C-%E4%BD%B3%E6%B3%B0%E8%8E%B1%C2%AE)-approved-for-marketing-by-nmpa-of-china-for-2l%2B-advanced-or-metastatic-tnbc 2025-01-23 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-trop2-adc-skb264-(sac-tmt)-third-nda-for-egfr-mutant-nsclc-accepted-by-nmpa 2025-01-08 https://www.kluspharma.com/news/multiple-study-results-of-kelun-biotech%E2%80%99s-trop2-adc-skb264-(sac-tmt)-presented-at-2024-csco-congress 2025-01-03 https://www.kluspharma.com/news/multiple-study-results-for-kelun-biotech's-trop2-adc-(sac-tmt)-were-presented-at-2024-esmo-congress 2024-11-27 https://www.kluspharma.com/news/three-study-result-abstracts-from-kelun-biotech%E2%80%99s-trop2-adc-sac-tmt-(skb264)-released-today-at-2024-esmo- 2024-10-31 https://www.kluspharma.com/news/klus-pharma-to-attend-the-15th-annual-world-adc-in-san-diego 2024-09-19 https://www.kluspharma.com/news/klus-pharma-to-attend-the-adc-%26-radiopharmaceuticals-pharma-and-biotech-partnering-summit 2024-09-30 https://www.kluspharma.com/news/klus-pharma-to-attend-esmo-congress-2024 2024-09-11 https://www.kluspharma.com/news/kelun-biotech%E2%80%99s-trop2-adc-skb264-(sac-tmt)-second-nda-accepted-by-npma%2C-locally-advanced-or-metastatic-egfr-mutant-nsclc 2024-09-05 https://www.kluspharma.com/news/two-abstracts-of-skb264%2Fsac-tmt-(trop2-adc)-published-at-2024-asco-annual-meeting 2024-09-05 https://www.kluspharma.com/news/kelun-biotech-and-ellipses-a400-(ep0031)-cleared-to-start-ph2-clinical-development-by-us-fda 2024-09-05 https://www.kluspharma.com/news/klus-pharma-to-attend-2024-bio-international-convention-in-san-diego-(june-3-6) 2024-08-20 https://www.kluspharma.com/news/kelun-biotech-to-present-two-abstracts-for-skb264-(mk-2870)-at-aacr-annual-meeting- 2024-05-24 https://www.kluspharma.com/news/klus-pharma-to-attend-aacr-annual-meeting-2024 2024-05-06 https://www.kluspharma.com/news/klus-pharma-to-attend-bio-europe-spring-2024 2024-04-08 https://www.kluspharma.com/news/klus-pharma-to-attend-14th-world-adc-london-2024 2024-05-01 https://www.kluspharma.com/news/kelun-biotech-announces-the-latest-clinical-study-results-of-skb264-(mk-2870)-for-the-treatment-of--tnbc-at-2023-sabcs 2024-03-04 https://www.kluspharma.com/news/kelun-biotech-announced-that-a400%2Fep0031-has-been-granted-orphan-drug-designation-by-fda- 2024-03-04 https://www.kluspharma.com/news/kelun-biotech-to-present-clinical-updates-for-skb264-at-2023-esmo 2024-03-04 https://www.kluspharma.com/news/kelun-biotech-successfully-listed-on-the-main-board-of-hkex 2023-12-08 https://www.kluspharma.com/news/skb264-(mk-2870)-is-approved-for-clinical-trials-in-the-european-union 2023-11-29 https://www.kluspharma.com/news/kelun-biotech-to-present-recent-clinical-data-for-skb264-(trop2-adc)-at-asco-2023 2023-08-10 https://www.kluspharma.com/news/klus-pharma-to-attend-2023-asco-annual-meeting 2023-07-18 https://www.kluspharma.com/news/klus-pharma-to-attend-the-2023-bio-international-convention- 2023-06-22 https://www.kluspharma.com/news/klus-pharma-to-attend-2023-aacr-annual-meeting 2023-05-28 https://www.kluspharma.com/news/klus-pharma-is-attending-2023-bio-europe-spring! 2023-05-28 https://www.kluspharma.com/news/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer 2023-04-13 https://www.kluspharma.com/news/2022-sabcs-%7C-kelun-biotech-trop2-adc-(skb264%2C-mk-2870)-phase-2-study-poster 2023-04-13 https://www.kluspharma.com/news/klus-pharma-is-attending-bio-partnering-at-jpm-2023! 2023-03-15 https://www.kluspharma.com/news/klus-pharma-is-attending-biopharm-america-in-boston! 2022-12-22 https://www.kluspharma.com/news/kelun-biotech-announces-oncology-research-collaboration-and-license-agreement-with-msd 2022-12-22 https://www.kluspharma.com/news/a400%2Fep0031-obtains-ind-approval-from-fda 2022-11-14 https://www.kluspharma.com/news/updates-for-a166-(her2-adc)-will-be-presented-at-2022-asco-annual-meeting 2022-11-14 https://www.kluspharma.com/news/klus-pharma-is-attending-bio-international-convention-in-san-diego! 2022-07-26 https://www.kluspharma.com/news/klus-pharma-is-attending-bio-europe-spring-2022 2022-06-29 https://www.kluspharma.com/news/klus-pharma-is-attending-40th-annual-j.p.-morgan-health-care-conference 2022-05-30 https://www.kluspharma.com/news/kelun-biotech-will-present-an-update-on-skb264-at-2021-esmo 2022-03-22 https://www.kluspharma.com/news/klus-pharma-is-attending-2021-biopharm-america-digital-conference 2022-05-27 https://www.kluspharma.com/news/kelun-biotech-will-present-updates-for-a166-at-asco 2021-09-11 https://www.kluspharma.com/news/klus-pharma-is-attending-bio-international-convention-digital-event 2021-09-11 https://www.kluspharma.com/news/kelun-biotech-and-ellipses-pharma-announce-a-licensing-agreement-for-a400 2022-05-27 https://www.kluspharma.com/news/klus-pharma-is-attending-bio-europe-spring 2022-05-27 https://www.kluspharma.com/news/klus-pharma-is-attending-bio-partnering-at-jpm 2022-05-27 https://www.kluspharma.com/news/looking-for-partnerships-to-combat-covid-19 2022-05-27 https://www.kluspharma.com/news/ind-for-kl-a289-is-approved-in-china 2022-05-27 https://www.kluspharma.com/news/klus-pharma-to-present-at-bio-digital- 2022-05-27 https://www.kluspharma.com/news/klus-pharma-to-present-at-asco-annual-meeting- 2022-05-27